Research pipeline
We combine the pioneering science of our collaborators with the recognised expertise of our core partners. Together, we are advancing a pipeline of potential first-in-class or best-in-class, child-focused therapeutic assets to address some of the most challenging indications in paediatric cancer.
CF-012
A potential first-in-class, ETV6 inhibitor for the treatment of Ewing sarcoma
In collaboration with:
University of Virginia
Dana-Farber Cancer Institute
Mass General Brigham
CF-033
A potential first-in-class allogeneic, PRAME-targeting iNKT cell therapy to treat advanced cancers in young patients
In collaboration with:
MiNK Therapeutics
University of Southampton
Work with us
Whether you’re a researcher with a therapeutic opportunity, a potential partner or an impact investor, we want to hear from you.
Interested in collaborating with us?
Do you work on promising science in paediatric cancer? Read more about our process and get in touch with our team to figure out how your research could fit into our pipeline.
Learn more
Partnering & investment opportunities
Are you an investor, or interested in partnering opportunities?
Explore partnering
News and events
We are creating a consortium united in the unwavering belief that we can challenge conventional approaches and accelerate translation of promising ideas into new therapies for children and young people affected by cancer.
Stay up to date on our latest news, events and research.
Why we need to rethink childhood cancer treatments (Drug Discovery World editorial)
Tom Edwards, our Partnering Lead, examines why childhood cancer has lagged behind adult oncology innovation and what is changing to drive progress for children with cancer.
Building the future of childhood cancer medicines
Listen to Tony Hickson and Labiotech’s Dylan Kissane discuss how C-Further is accelerating child-first medicines for children and young people with cancer.
Inside C-Further’s operating model
In the article , we outline our framework and how our hybrid model creates long-term value and clinical impact.
What makes a strong C-Further collaboration proposal
In this article, we outline our evaluation framework and share what researchers and future partners from academia and industry should consider when preparing a collaboration proposal.